Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01962792 · OUTCOME

Progression Free Survival (PFS)

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2021-12-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 4 years

What was measured

Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.

Analysis population: Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All RP2D population (per protocol).

Groups in this outcome

All RP2D (840 mg)

Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg Ibrutinib Carfilzomib Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All RP2D (840 mg)59

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All RP2D (840 mg)7.4Not reported4.610.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.6
        upper Limit
        10.2
        value
        7.4
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
Time from date of first dose of study treatment to the date of first documented evidence of progressive disease, death or date of censoring for the subjects not progressed/died. The censoring date was the last adequate tumor assessment date.
dispersion Type
95% Confidence Interval
groups
  1. description
    Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg Ibrutinib Carfilzomib Dexamethasone
    id
    OG000
    title
    All RP2D (840 mg)
param Type
MEDIAN
population Description
Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All RP2D population (per protocol).
reporting Status
POSTED
time Frame
Up to 4 years
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice